NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback